ID: ALA2407628

Max Phase: Preclinical

Molecular Formula: C29H34BrN7O2S

Molecular Weight: 624.61

Molecule Type: Small molecule

Representations

Canonical SMILES:  CSc1nc(N(C(=O)OCCN2CCN(C)CC2)c2cccc(Br)c2)c2cnn(CC(C)c3ccccc3)c2n1

Standard InChI:  InChI=1S/C29H34BrN7O2S/c1-21(22-8-5-4-6-9-22)20-36-26-25(19-31-36)27(33-28(32-26)40-3)37(24-11-7-10-23(30)18-24)29(38)39-17-16-35-14-12-34(2)13-15-35/h4-11,18-19,21H,12-17,20H2,1-3H3

Standard InChI Key:  MVGQVUFEKIVQTO-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 624.61

Molecular Weight (Monoisotopic): 623.1678

AlogP: 5.64

#Rotatable Bonds: 9

Polar Surface Area: 79.62

Molecular Species: NEUTRAL

HBA: 9

HBD: 0

#RO5 Violations: 2

HBA (Lipinski): 9

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 7.70

CX LogP: 6.16

CX LogD: 5.68

Aromatic Rings: 4

Heavy Atoms: 40

QED Weighted: 0.18

Np Likeness Score: -1.63

References

1. Vignaroli G, Zamperini C, Dreassi E, Radi M, Angelucci A, Sanità P, Crespan E, Kissova M, Maga G, Schenone S, Musumeci F, Botta M..  (2013)  Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors.,  4  (7): [PMID:24900720] [10.1021/ml4000782]

2. Vignaroli G, Iovenitti G, Zamperini C, Coniglio F, Calandro P, Molinari A, Fallacara AL, Sartucci A, Calgani A, Colecchia D, Mancini A, Festuccia C, Dreassi E, Valoti M, Musumeci F, Chiariello M, Angelucci A, Botta M, Schenone S..  (2017)  Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model.,  60  (14): [PMID:28650650] [10.1021/acs.jmedchem.7b00637]

Source

Source(1):

• Scientific Literature